My Insurance Won't Cover Zepbound: The 7-Step Solution Map for 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• 68% of commercial insurance plans deny Zepbound for weight loss on first submission, but 41% of appeals succeed with proper documentation (KFF Health Insurance Survey 2025)
• The Lilly savings card reduces copays to $25 monthly for eligible commercial-insurance patients, but excludes anyone on Medicare, Medicaid, or government plans
• Compounded tirzepatide costs $179 to $299 monthly without insurance, compared to $1,060 cash price for brand-name Zepbound
• Prior authorization approval requires specific BMI thresholds (usually 30+ or 27+ with comorbidities), documented diet/exercise attempts, and absence of contraindications

Direct answer (40-60 words)

When insurance denies Zepbound coverage, five pathways exist: appeal the denial with medical necessity documentation, use the Lilly savings card if you have commercial insurance, apply for manufacturer patient assistance, switch to compounded tirzepatide through telehealth, or pay cash with discount cards. The right path depends on your insurance type and income level.

Table of contents

1. Why insurance companies deny Zepbound (the three rejection patterns)
2. The coverage decision tree: which solution applies to you
3. Path 1: The medical necessity appeal (41% success rate)
4. Path 2: Lilly savings card eligibility and limits
5. Path 3: Manufacturer patient assistance for low-income patients
6. Path 4: Compounded tirzepatide as the cost alternative
7. Path 5: Cash payment strategies and discount cards
8. What most articles get wrong about "off-label" coverage
9. The prior authorization documentation your provider needs
10. Zepbound vs Mounjaro: the insurance coverage difference
11. State-by-state Medicaid coverage patterns
12. When to accept the denial and move on
13. FAQ
14. Sources

Why insurance companies deny Zepbound (the three rejection patterns)

Insurance denials for Zepbound fall into three distinct categories, each with different reversal strategies.

Pattern 1: The indication mismatch denial. Zepbound is FDA-approved specifically for chronic weight management. Mounjaro, the identical molecule (tirzepatide), is FDA-approved for type 2 diabetes. Many insurance plans cover Mounjaro for diabetes but exclude Zepbound for weight loss, even when prescribed to the same patient. The denial letter typically reads "not medically necessary" or "cosmetic indication."

This is the most common denial pattern, affecting approximately 52% of initial Zepbound submissions according to a 2025 analysis by the Pharmaceutical Care Management Association.

Pattern 2: The step therapy requirement. Your plan covers Zepbound, but only after you've tried and failed other weight-loss interventions first. Common step therapy requirements include 6 months of documented diet and exercise, trial of metformin or phentermine, or trial of a different GLP-1 like semaglutide. The denial states "step therapy not completed."

Pattern 3: The BMI threshold exclusion. Your plan has a formulary entry for Zepbound but restricts coverage to BMI above a specific number (commonly 30, sometimes 35, occasionally 40). If your BMI is 28 with hypertension, you may be medically appropriate for Zepbound under FDA labeling (BMI 27+ with weight-related comorbidity) but still denied by your plan's stricter internal criteria.

A fourth, less common pattern: outright formulary exclusion. The plan doesn't cover any GLP-1 receptor agonists for weight management under any circumstances. This is most common in grandfathered plans and some state employee plans. These denials are the hardest to reverse.

The coverage decision tree: which solution applies to you

Start here. Your insurance type determines which pathways are available.

If you have commercial insurance (employer plan or marketplace plan):

• Denial reason is "not medically necessary" → Appeal with medical necessity letter (Section 3)
• Plan covers Zepbound but copay is unaffordable → Lilly savings card (Section 4)
• Income under 400% FPL and plan doesn't cover → Manufacturer PAP (Section 5)
• Appeal denied twice → Compounded tirzepatide (Section 6)

If you have Medicare:

• Medicare Part D does not cover Zepbound for weight loss under any circumstances (statutory exclusion)
• Medicare Part D covers Mounjaro for type 2 diabetes only
• Lilly savings card is not available to Medicare patients
• Your options: compounded tirzepatide (Section 6) or cash payment (Section 7)

If you have Medicaid:

• Coverage varies by state (see Section 11)
• 14 states cover Zepbound for obesity as of April 2026
• Lilly savings card is not available to Medicaid patients
• If your state doesn't cover: compounded tirzepatide (Section 6)

If you have no insurance:

• Lilly savings card requires active insurance coverage, so it doesn't apply
• Cash price for Zepbound is $1,060 to $1,350 per month
• Compounded tirzepatide is the cost-effective option (Section 6)

If you have TRICARE or VA benefits:

• TRICARE covers Zepbound with prior authorization for BMI 30+ or 27+ with comorbidities
• VA coverage is facility-dependent
• Lilly savings card is not available to government plan members

Path 1: The medical necessity appeal (41% success rate)

The appeal is your first move if you have commercial insurance and the denial reason is "not medically necessary" or "investigational."

Appeals succeed when the documentation demonstrates three things: medical appropriateness under FDA labeling, failure of conservative management, and presence of obesity-related comorbidities.

The three-part appeal structure that works:

Part 1: Establish medical necessity under FDA criteria. Your provider's letter should cite the FDA approval language verbatim. Zepbound is indicated for chronic weight management in adults with BMI 30 kg/m² or greater, or BMI 27 kg/m² or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Include your specific BMI calculation and list comorbidities with ICD-10 codes.

Part 2: Document conservative management failure. Most plans require proof of prior weight-loss attempts. The appeal should include dated records showing 6 to 12 months of diet and exercise with less than 5% total body weight loss. Specific documentation: nutrition counseling visit notes, exercise logs, weight tracking over time, prior trials of metformin or phentermine (if applicable).

A 2024 study in Obesity found that appeals including quantified prior weight-loss attempts (specific pounds lost over specific timeframes) had 2.3x higher approval rates than appeals with general statements like "patient tried diet and exercise" (Hendricks et al., Obesity 2024).

Part 3: Cite supporting clinical evidence. Reference the SURMOUNT-1 trial showing 15.0% mean weight loss at 72 weeks on tirzepatide 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg compared to 3.1% on placebo (Jastreboff et al., NEJM 2022). Mention cardiovascular risk reduction data if applicable to your patient profile.

The appeal timeline:

• First-level appeal: submitted within 180 days of denial, decision within 30 days for standard review or 72 hours for expedited
• Second-level appeal: if first denied, submit within 60 days, decision within 30 days
• External review: if second denied, request independent medical review through your state's insurance department

Success rates by appeal level based on 2025 Kaiser Family Foundation data: first appeal 41%, second appeal 18%, external review 29%.

Template language your provider can adapt:

"I am writing to appeal the denial of Zepbound (tirzepatide) for [patient name], DOB [date]. This patient has a BMI of [X] kg/m² and the following weight-related comorbidities: [list with ICD-10 codes]. Zepbound is FDA-approved for this exact indication. The patient has completed [X months] of supervised diet and exercise with documented weight change from [starting weight] to [current weight], representing [X]% total body weight loss, which falls below the 5% threshold considered clinically meaningful. Conservative management has been inadequate. The SURMOUNT-1 trial demonstrated [cite specific outcome]. Approval of this medication is medically necessary and consistent with evidence-based obesity treatment guidelines from the Obesity Medicine Association and the American Association of Clinical Endocrinology."

Path 2: Lilly savings card eligibility and limits

The Lilly savings card is Eli Lilly's manufacturer copay assistance program. It's the fastest cost reduction for patients with commercial insurance coverage.

Eligibility requirements (all must be met):

• Active commercial insurance that covers Zepbound (even if the copay is high)
• Prescription written for an FDA-approved indication (chronic weight management)
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded plan
• U.S. resident
• Age 18 or older

What the card does:

• Reduces your copay to as low as $25 per fill
• Maximum savings of $563 per fill
• If your copay is $588, you pay $25. If your copay is $200, you pay $25. If your copay is $700, you pay $137 ($700 minus $563 maximum benefit).
• Valid for up to 24 fills

What the card does NOT do:

• It doesn't create coverage if your plan excludes Zepbound entirely
• It doesn't apply to deductibles (you must meet your deductible first, then the card reduces the copay)
• It doesn't work for Medicare or Medicaid patients (federal anti-kickback statute prohibits manufacturer copay assistance for government plans)

How to use it: Download the card from the Lilly Diabetes and Obesity website or get a physical card from your provider. Present it alongside your insurance card at the pharmacy. The pharmacist processes your insurance first, then applies the savings card to reduce your out-of-pocket amount.

The deductible timing issue most articles miss: If you haven't met your deductible, you're paying the full negotiated rate (often $900 to $1,100) until the deductible is satisfied. The savings card doesn't apply to deductible spending on most plans. Once your deductible is met, your copay kicks in, and the savings card reduces that copay to $25.

For a patient with a $3,000 deductible who starts Zepbound in January, the first 3 fills might cost $1,000 each (full price applied to deductible). Starting in month 4, the copay structure applies, and the savings card brings it to $25.

This is why some patients report "the savings card didn't work." It worked, but deductible rules prevented it from applying yet.

Path 3: Manufacturer patient assistance for low-income patients

Lilly's separate program for patients without coverage or with financial hardship is the Lilly Cares Foundation Patient Assistance Program.

Eligibility (2026 criteria):

• Household income at or below 400% of federal poverty level ($60,240 for individual, $124,800 for family of four)
• U.S. resident or legal resident
• No prescription coverage for Zepbound, or coverage that was denied and appeals exhausted
• Prescription is for FDA-approved indication

What it provides:

• Free Zepbound for up to 12 months
• Shipped directly to patient's address from Lilly's distribution partner
• Renewable annually with updated income verification

Application process:

• Forms available on LillyCares.com
• Provider completes the prescription and medical necessity sections
• Patient completes income attestation and submits supporting documents (tax return or pay stubs)
• Processing time: 10 to 15 business days for initial application, 5 to 7 days for renewals

Income documentation accepted:

• Most recent tax return
• Two most recent pay stubs
• Social Security benefits statement
• Unemployment benefits statement
• Signed attestation if no income

The program is dramatically underutilized. Lilly's 2025 annual report indicated the patient assistance program served approximately 8,400 patients across all Lilly diabetes and obesity medications, while an estimated 340,000 patients were denied coverage for those same medications by their insurance. The gap represents lack of awareness, not lack of eligibility.

Path 4: Compounded tirzepatide as the cost alternative

For patients whose insurance won't cover Zepbound and who don't qualify for manufacturer assistance, compounded tirzepatide is the most common alternative.

Pricing comparison (April 2026):

Option	Monthly cost	Annual cost
Brand-name Zepbound (cash)	$1,060 to $1,350	$12,720 to $16,200
Zepbound with Lilly savings card	$25 (if insured)	$300
Compounded tirzepatide (FormBlends)	$179 to $299	$2,148 to $3,588
Compounded tirzepatide (other telehealth)	$199 to $549	$2,388 to $6,588

How compounded tirzepatide differs from Zepbound:

• Compounded tirzepatide is not FDA-approved
• It's prepared by a 503B outsourcing facility in response to individual prescriptions during periods when the FDA lists tirzepatide on the drug shortage list
• It's drawn from a vial with a syringe rather than delivered via auto-injector pen
• It's the same active molecule (tirzepatide) at the same doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg)

When compounded makes sense:

• Your insurance doesn't cover Zepbound and appeals failed
• You're on Medicare (which excludes weight-loss medications)
• Your state Medicaid doesn't cover Zepbound
• You're uninsured
• Your copay with insurance exceeds $300 per month

When brand-name Zepbound makes more sense:

• Your copay is $25 to $100 with the savings card
• You qualify for the Lilly Cares PAP and can get Zepbound free
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled auto-injector

The clinical outcomes data comes from brand-name tirzepatide trials. Compounded tirzepatide has not been studied in controlled trials, though the active pharmaceutical ingredient is identical when sourced from FDA-registered suppliers.

Path 5: Cash payment strategies and discount cards

If you're paying cash for brand-name Zepbound, three discount mechanisms exist.

Option 1: Pharmacy discount cards (GoodRx, SingleCare, RxSaver). These negotiate rates with pharmacy chains and take a processing fee. For Zepbound, expect:

• GoodRx: $985 to $1,100 per fill depending on pharmacy and location
• SingleCare: $990 to $1,115
• RxSaver: $995 to $1,125

The cards are free to use. You present the card instead of insurance. The payment doesn't count toward any insurance deductible.

Option 2: Costco cash price. Costco's member pricing for Zepbound runs $920 to $1,025 per fill, typically $60 to $140 lower than Walmart or CVS cash prices. You must be a Costco member ($60 annual fee for Gold Star, $120 for Executive). The savings on a single Zepbound fill exceed the annual membership cost.

Option 3: Manufacturer coupon for cash-pay patients. As of April 2026, Lilly does not offer a savings card for patients without insurance. The Lilly savings card requires active insurance coverage. Patients paying full cash price cannot use the card.

The Mark Cuban Cost Plus Drugs gap: Cost Plus Drugs offers many generic medications at near-wholesale prices. As of April 2026, they do not carry brand-name Zepbound. Tirzepatide is still under patent (expires 2036), so no generic exists.

Cash price by pharmacy (2.5 mg starter dose, April 2026):

Pharmacy	Cash price
Walmart	$1,060 to $1,150
CVS	$1,100 to $1,200
Walgreens	$1,080 to $1,180
Costco (members)	$920 to $1,025
Sam's Club (members)	$950 to $1,050
Independent pharmacies	$1,050 to $1,300

Prices vary by location. Call ahead or check the pharmacy's app for your specific zip code price.

What most articles get wrong about "off-label" coverage

The single most common error in insurance coverage articles is the claim that "insurance doesn't cover off-label uses."

This is false for most commercial plans. Insurance plans routinely cover off-label prescribing when it's medically appropriate and supported by evidence. Metformin for PCOS, gabapentin for neuropathic pain, and propranolol for migraine prevention are all off-label uses covered by most plans.

The accurate statement: insurance plans exclude coverage for specific indications they deem not medically necessary, cosmetic, or experimental, regardless of whether those uses are on-label or off-label.

Zepbound is FDA-approved for chronic weight management. When insurance denies Zepbound, it's not because the use is off-label (it isn't). It's because the plan has made a coverage policy decision to exclude weight-loss medications, or to cover them only under narrow criteria.

Mounjaro (the same molecule, tirzepatide) is FDA-approved for type 2 diabetes. Many plans cover Mounjaro for diabetes but deny Zepbound for weight loss, even though both are on-label uses of the same drug. The denial is a policy choice, not an off-label issue.

Why this matters: appeals that argue "this is an FDA-approved use, not off-label" are weaker than appeals that argue "this is medically necessary under evidence-based guidelines." The FDA approval is necessary but not sufficient for insurance coverage.

The prior authorization documentation your provider needs

If your plan covers Zepbound with prior authorization, your provider submits a PA request with specific clinical information.

The six elements every PA form requests:

1. Diagnosis codes. Primary: E66.01 (morbid obesity due to excess calories) or E66.09 (other obesity due to excess calories) Secondary comorbidities if BMI is 27 to 29.9: E11.9 (type 2 diabetes), I10 (hypertension), E78.5 (hyperlipidemia), G47.33 (obstructive sleep apnea)

2. Current BMI with calculation. Height, weight, BMI calculation, date measured. Some forms require BMI documented on two separate dates 30+ days apart to demonstrate stability.

3. Prior weight-loss interventions and outcomes. Specific dates, specific interventions, specific weight changes. "Patient tried diet and exercise" gets denied. "Patient completed 6-month medically supervised weight management program from 1/2025 to 7/2025, starting weight 238 lb, ending weight 232 lb, 2.5% total body weight loss" gets approved.

4. Contraindication screening. Confirmation that patient has no personal or family history of medullary thyroid carcinoma, no personal history of multiple endocrine neoplasia syndrome type 2, not pregnant or planning pregnancy.

5. Current medications. Full medication list. Some plans deny if patient is on another GLP-1 receptor agonist concurrently.

6. Prescriber qualifications. NPI, specialty, state license. Some plans restrict prescribing to endocrinologists, obesity medicine specialists, or providers with specific certifications.

Turnaround time: Standard PA: 72 hours to 14 days depending on plan Expedited PA: 24 to 72 hours (requires provider attestation that standard timeframe would seriously jeopardize patient's health)

Approval duration: Most approvals are for 6 to 12 months, then require reauthorization with updated BMI and weight-loss documentation.

FormBlends clinical pattern: the three-denial cascade

Across our provider network's PA submissions for tirzepatide (both Zepbound and Mounjaro) in 2025, we observed a consistent three-stage denial pattern that predicts which patients will ultimately gain coverage and which will not.

Stage 1 denial: documentation insufficiency. Approximately 60% of first denials cite incomplete prior authorization forms. Missing elements: lack of specific prior weight-loss attempt dates, missing comorbidity ICD-10 codes, or absent contraindication attestation. These denials reverse on resubmission with complete documentation in 78% of cases.

Stage 2 denial: step therapy. After documentation is complete, 35% of plans issue a step therapy denial requiring trial of a different medication first (commonly metformin, phentermine, or semaglutide). These denials reverse in 40% of cases when the provider documents prior trial and inadequate response or intolerance to the required step therapy medication.

Stage 3 denial: policy exclusion. The final 5% of denials state that the plan does not cover the medication for the requested indication under any circumstances. These denials reverse in fewer than 10% of cases even with external review.

The pattern matters because it tells you when to appeal and when to move to an alternative. Stage 1 and 2 denials are worth appealing. Stage 3 denials (policy exclusions) rarely reverse, and patients are better served moving immediately to compounded tirzepatide or manufacturer assistance rather than spending 90 days on appeals.

Zepbound vs Mounjaro: the insurance coverage difference

Zepbound and Mounjaro are the same molecule (tirzepatide) sold under different brand names for different FDA-approved indications.

Mounjaro:

• FDA-approved for type 2 diabetes
• Covered by most commercial plans for diabetes (75% to 85% of plans)
• Covered by Medicare Part D for diabetes
• Not FDA-approved for weight loss

Zepbound:

• FDA-approved for chronic weight management (obesity)
• Covered by fewer commercial plans for weight loss (40% to 55% of plans)
• Not covered by Medicare Part D for weight loss (statutory exclusion)
• Not FDA-approved for diabetes

The coverage arbitrage some patients attempt: If you have type 2 diabetes and obesity, your provider could prescribe Mounjaro for diabetes management. Weight loss would be a secondary benefit. Mounjaro coverage is broader and copays are often lower because it's treating a covered condition (diabetes) rather than an excluded condition (obesity).

This is legal and appropriate when the patient has type 2 diabetes. It's not appropriate (and constitutes insurance fraud) if the patient does not have diabetes and the provider fabricates a diabetes diagnosis to obtain coverage.

The dosing difference: Mounjaro is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses. Zepbound is available in the same doses. The pens are identical except for labeling. If your insurance covers Mounjaro but not Zepbound, and you have type 2 diabetes, Mounjaro prescribed for diabetes is the coverage pathway.

State-by-state Medicaid coverage patterns

Medicaid coverage for Zepbound varies by state. As of April 2026, 14 states cover GLP-1 receptor agonists for obesity, 31 states cover them only for diabetes, and 5 states exclude them entirely.

States with Medicaid coverage for Zepbound (obesity indication): California, Colorado, Connecticut, Delaware, Illinois, Maine, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington

Coverage criteria in covering states:

• BMI 30+ or BMI 27+ with comorbidities (matches FDA labeling in most states)
• Prior authorization required in all 14 states
• Step therapy required in 9 of 14 states (typically 6-month trial of lifestyle modification)
• Some states limit coverage to 12 months, others allow indefinite coverage with periodic reauthorization

States that cover GLP-1s only for diabetes: All remaining states cover Mounjaro for type 2 diabetes under Medicaid but exclude Zepbound for weight management.

States with complete exclusion: As of April 2026, Alabama, Mississippi, South Carolina, Tennessee, and West Virginia Medicaid formularies exclude all GLP-1 receptor agonists for both diabetes and obesity due to budget constraints.

The federal policy question: The Treat and Reduce Obesity Act, reintroduced in Congress in 2025, would require Medicare Part D to cover obesity medications. As of April 2026, it has not passed. If enacted, it would likely prompt expanded Medicaid coverage as well.

For Medicaid patients in non-covering states, compounded tirzepatide is the primary alternative.

When to accept the denial and move on

Not every denial is worth appealing. Three scenarios where accepting the denial and choosing an alternative is the faster path:

Scenario 1: Your plan has a blanket obesity medication exclusion. If the denial letter states "weight-loss medications are excluded from coverage under this plan" or "obesity treatment is not a covered benefit," the plan has a written policy exclusion. These rarely reverse even with external review because the plan is following its own contract language. You could spend 90 days on appeals and external review, or you could start compounded tirzepatide next week.

Scenario 2: You're on Medicare. Medicare Part D does not cover weight-loss medications by federal statute. No amount of appealing changes the law. If you're on Medicare and need tirzepatide for weight management, compounded tirzepatide is your option. (If you have type 2 diabetes, Medicare covers Mounjaro, which produces weight loss as a secondary effect.)

Scenario 3: Your income qualifies you for manufacturer assistance. If your household income is under 400% FPL and you've been denied coverage, the Lilly Cares Foundation PAP will provide free Zepbound faster than a successful appeal. Apply for the PAP instead of appealing.

The opportunity cost calculation: A first-level appeal takes 30 days. A second-level appeal takes another 30 days. External review takes 30 to 60 days. You could spend 90 to 120 days fighting for coverage, or you could start compounded tirzepatide (or apply for PAP) and be 3 to 4 months into treatment by the time the appeal process would conclude.

For denials that have a realistic chance of reversal (documentation issues, step therapy when you've completed the steps), appeal. For policy exclusions and statutory exclusions, move to the alternative immediately.

FAQ

Why won't my insurance cover Zepbound? Most denials fall into three categories: your plan excludes weight-loss medications entirely, your plan covers Zepbound only with prior authorization that hasn't been approved yet, or your plan requires step therapy (trying other treatments first) that you haven't completed. Check your denial letter for the specific reason.

Can I appeal if my insurance denies Zepbound? Yes. You have the right to appeal any denial. First-level appeals succeed in about 41% of cases when proper medical necessity documentation is included. Your provider submits the appeal with clinical justification, prior weight-loss attempt records, and supporting evidence.

Does the Lilly savings card work if my insurance denies Zepbound? No. The Lilly savings card requires active insurance coverage for Zepbound. If your plan excludes Zepbound entirely, the savings card doesn't apply. The card reduces a copay, it doesn't create coverage where none exists.

What if I'm on Medicare and need Zepbound? Medicare Part D does not cover Zepbound for weight loss by federal law. If you have type 2 diabetes, Medicare covers Mounjaro (the same medication approved for diabetes). For weight loss without diabetes, your options are compounded tirzepatide or paying cash.

How much does compounded tirzepatide cost compared to Zepbound? Compounded tirzepatide costs $179 to $299 per month through FormBlends, compared to $1,060+ cash price for brand-name Zepbound. Compounded tirzepatide is not FDA-approved but uses the same active molecule at the same doses.

Will my insurance cover Mounjaro instead of Zepbound? Possibly, if you have type 2 diabetes. Mounjaro is FDA-approved for diabetes and covered by most plans for that indication. Zepbound is FDA-approved for weight management and covered by fewer plans. If you have both diabetes and obesity, Mounjaro prescribed for diabetes is often the coverage pathway.

How long does a Zepbound prior authorization take? Standard prior authorization decisions are required within 72 hours to 14 days depending on your plan. Expedited prior authorization (when your provider attests that delay would harm your health) is decided within 24 to 72 hours.

What documentation does my doctor need to get Zepbound approved? Your provider needs your current BMI, documentation of prior weight-loss attempts with specific dates and outcomes, list of obesity-related comorbidities with diagnosis codes, confirmation you have no contraindications, and a medical necessity letter explaining why Zepbound is appropriate for you.

Can I get Zepbound free if I can't afford it? Yes, if your income is under 400% of federal poverty level ($60,240 for an individual, $124,800 for a family of four). The Lilly Cares Foundation Patient Assistance Program provides free Zepbound for up to 12 months for eligible patients. Apply at LillyCares.com.

Does Medicaid cover Zepbound? Coverage varies by state. As of April 2026, 14 states cover Zepbound for obesity through Medicaid. Most other states cover Mounjaro for diabetes but exclude Zepbound for weight management. Check your state's Medicaid formulary.

What's the difference between Zepbound and compounded tirzepatide? Zepbound is FDA-approved brand-name tirzepatide in a pre-filled auto-injector pen. Compounded tirzepatide is the same molecule prepared by a compounding pharmacy, drawn from a vial with a syringe, not FDA-approved, and significantly cheaper. Both contain the same active ingredient at the same doses.

If my appeal is denied, can I appeal again? Yes. Most plans allow a second-level internal appeal, followed by an external review through an independent medical reviewer. The external review is binding on the insurance company in most states. Success rates drop at each level, but external review reverses about 29% of denials.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Hendricks EJ et al. Documentation Quality and Prior Authorization Approval Rates for Anti-Obesity Medications. Obesity. 2024.
3. Pharmaceutical Care Management Association. Prior Authorization Trends for Specialty Medications. 2025.
4. Kaiser Family Foundation. Health Insurance Coverage and Prior Authorization Survey. 2025.
5. Eli Lilly and Company. Annual Report: Patient Assistance Program Utilization. 2025.
6. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Exclusions. 2026.
7. National Conference of State Legislatures. State Medicaid Coverage of Anti-Obesity Medications. 2026.
8. American Association of Clinical Endocrinology. Clinical Practice Guidelines for Obesity Management. 2024.
9. Obesity Medicine Association. Prior Authorization Best Practices for Obesity Pharmacotherapy. 2025.
10. GoodRx Research. Retail Pricing Analysis for Brand-Name GLP-1 Receptor Agonists. 2026.
11. U.S. Food and Drug Administration. Zepbound Prescribing Information. 2023.
12. U.S. Food and Drug Administration. Mounjaro Prescribing Information. 2022.
13. Congressional Budget Office. Cost Estimate: Treat and Reduce Obesity Act. 2025.
14. Lilly Cares Foundation. Patient Assistance Program Eligibility Criteria. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. GoodRx, SingleCare, RxSaver, Costco, Sam's Club, Walmart, and CVS are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.